Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Sahlberg, Sara Häggblad ^a   Spiegelberg, Diana ^a   Glimelius, Bengt ^b   Stenerlöw, Bo ^a   Nestor, Marika ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; PROTEIN AKT 1; PROTEIN KINASE B; PROTEIN KINASE B BETA; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; GLYCOPROTEIN; ISOPROTEIN; LEUKOCYTE ANTIGEN; ONCOPROTEIN; PEPTIDE;

ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER STEM CELL; CDH1 GENE; CDH2 GENE; CELL ADHESION; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FN1 GENE; FOXC2 GENE; GAMMA RADIATION; GENE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SNAI1 GENE; SNAI2 GENE; TWIST1 GENE; VIM GENE; ZEB1 GENE; ZEB2 GENE; COLON TUMOR; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, CD24; ANTIGENS, CD44; CELL LINE, TUMOR; COLONIC NEOPLASMS; GLYCOPROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; NEOPLASTIC STEM CELLS; ONCOGENE PROTEIN V-AKT; PEPTIDES; PROTEIN ISOFORMS;

EID: 84899726033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094621     Document Type: Article

References (65)

1. Rich JN (2007) Cancer stem cells in radiation resistance. Cancer Res 67: 8980-8984.
2. Abdullah LN, Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2: 3.
3. Baumann M, Krause M, Thames H, Trott K, Zips D (2009) Cancer stem cells and radiotherapy. Int J Radiat Biol 85: 391-402.
4. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, et al. (2009) Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 124: 1312-1321.
5. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, et al. (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15: 2258-2264.
6. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, et al. (2005) Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11: 6574-6581. (Pubitemid 41338997)
7. Ke J, Wu X, He X, Lian L, Zou Y, et al. (2012) A subpopulation of CD24(+) cells in colon cancer cell lines possess stem cell characteristics. Neoplasma 59: 282-288.
8. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231. (Pubitemid 40585308)
9. Spiegelberg D, Kuku G, Selvaraju R, Nestor M (2013) Characterization of CD44 variant expression in head and neck squamous cell carcinomas. Tumour Biol.
10. Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, et al. (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219: 427-434.
11. Du L, Wang H, He L, Zhang J, Ni B, et al. (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14: 6751-6760.
12. Banky B, Raso-Barnett L, Barbai T, Timar J, Becsagh P, et al. (2012) Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer 11: 83.
13. Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, et al. (2002) CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol 10: 34-39. (Pubitemid 34178274)
14. Ma L, Zhang G, Miao XB, Deng XB, Wu Y, et al. (2013) Cancer stem-like cell properties are regulated by EGFR/AKT/beta-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS J 280: 2027-2041.
15. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, et al. (2012) CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012 41: 211-218.
16. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274. (Pubitemid 46962095)
17. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86. (Pubitemid 41202364)
18. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. (Pubitemid 351636299)
19. Chen KL, Pan F, Jiang H, Chen JF, Pei L, et al. (2011) Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis 28: 751-763.
20. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758. (Pubitemid 351380265)
21. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, et al. (2010) Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133 + primary colon cancer cells. Carcinogenesis 31: 1376-1380.
22. Zhang LS, Ma HW, Greyner HJ, Zuo W, Mummert ME (2010) Inhibition of cell proliferation by CD44: Akt is inactivated and EGR-1 is down-regulated. Cell Prolif 43: 385-395.
23. Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, et al. (2007) CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 83: 207-215. (Pubitemid 47320661)
24. Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, et al. (2011) Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 52: 1758-1769.
25. Bates R, Edwards N, Burns G, Fisher D (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer research 61: 5275-5283. (Pubitemid 32681564)
26. Kawamoto A, Tanaka K, Saigusa S, Toiyama Y, Morimoto Y, et al. (2012) Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 3: 403-409.
27. Sahlberg SH, Gustafsson AS, Pendekanti PN, Glimelius B, Stenerlow B (2013) The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol.
28. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
29. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36. (Pubitemid 32095858)
30. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
31. Benjamini Y HY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B: 289-300.
32. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
33. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
34. Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, et al. (2012) Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg 147: 18-24.
35. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, et al. (2008) CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 15: 2927-2933.
36. Butof R, Dubrovska A, Baumann M (2013) Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 108: 388-396.
37. Botchkina G (2013) Colon cancer stem cells-from basic to clinical application. Cancer Lett 338: 127-140.
38. Muraro MG, Mele V, Daster S, Han J, Heberer M, et al. (2012) CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med 1: 592-603.
39. Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB (2009) Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 75: 1216-1225.
40. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760. (Pubitemid 44949604)
41. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, et al. (2010) Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 113: 310-318.
42. Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554. (Pubitemid 351881850)
43. Blazek ER, Foutch JL, Maki G (2007) Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67: 1-5. (Pubitemid 44959518)
44. Baumann M, Krause M (2010) CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 16: 5091-5093.
45. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24 (2/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785. (Pubitemid 46017929)
46. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, et al. (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104: 618-623. (Pubitemid 46123074)
47. Du Z, Qin R, Wei C, Wang M, Shi C, et al. (2011) Pancreatic cancer cells resistant to chemoradiotherapy rich in ''stem-cell-like'' tumor cells. Dig Dis Sci 56: 741-750.
48. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, et al. (2010) Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 24: 345-350.
49. Chen S, Song X, Chen Z, Li X, Li M, et al. (2013) CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 8: e56380.
50. Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, et al. (2009) CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother Oncol 92: 353-361.
51. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
52. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115. (Pubitemid 46067311)
53. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, et al. (2003) Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159: 283-300. (Pubitemid 36314943)
54. Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697: 3-16. (Pubitemid 38326757)
55. Arden KC (2004) FoxO: linking new signaling pathways. Mol Cell 14: 416-418.
56. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, et al. (1999) Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523. (Pubitemid 29094101)
57. Kawamoto H, Yuasa T, Kubota Y, Seita M, Sasamoto H, et al. (2010) Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant 19: 857-864.
58. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7: e1000121.
59. Yang J, Zhang W, Evans PM, Chen X, He X, et al. (2006) Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 281: 17751-17757. (Pubitemid 44035574)
60. Kaler P, Augenlicht L, Klampfer L (2012) Activating mutations in beta-catenin in colon cancer cells alter their interaction with macrophages; the role of snail. PLoS One 7: e45462.
61. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, et al. (2011) Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10: 2331-2338.
62. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106: 268-273.
63. Louderbough JM, Schroeder JA (2011) Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res 9: 1573-1586.
64. Peng Z, Weber JC, Han Z, Shen R, Zhou W, et al. (2012) Dichotomy effects of Akt signaling in breast cancer. Mol Cancer 11: 61.
65. Lakshman M, Subramaniam V, Rubenthiran U, Jothy S (2004) CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol 77: 18-25. (Pubitemid 38822923)